Literature DB >> 27310333

Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.

David Liu1, Elizabeth R Plimack2, Jean Hoffman-Censits3, Levi A Garraway4, Joaquim Bellmunt1, Eliezer Van Allen4, Jonathan E Rosenberg5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27310333      PMCID： PMC5515075          DOI： 10.1001/jamaoncol.2016.1056

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

1.  Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.

Authors:  Takahisa Furuta; Takahiro Ueda; Gregory Aune; Alain Sarasin; Kenneth H Kraemer; Yves Pommier
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

2.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

Authors:  Eliezer M Van Allen; Kent W Mouw; Philip Kim; Gopa Iyer; Nikhil Wagle; Hikmat Al-Ahmadie; Cong Zhu; Irina Ostrovnaya; Gregory V Kryukov; Kevin W O'Connor; John Sfakianos; Ilana Garcia-Grossman; Jaegil Kim; Elizabeth A Guancial; Richard Bambury; Samira Bahl; Namrata Gupta; Deborah Farlow; Angela Qu; Sabina Signoretti; Justine A Barletta; Victor Reuter; Jesse Boehm; Michael Lawrence; Gad Getz; Philip Kantoff; Bernard H Bochner; Toni K Choueiri; Dean F Bajorin; David B Solit; Stacey Gabriel; Alan D'Andrea; Levi A Garraway; Jonathan E Rosenberg
Journal:  Cancer Discov       Date:  2014-08-05       Impact factor: 39.397

3.  Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

Authors:  Elizabeth R Plimack; Roland L Dunbrack; Timothy A Brennan; Mark D Andrake; Yan Zhou; Ilya G Serebriiskii; Michael Slifker; Katherine Alpaugh; Essel Dulaimi; Norma Palma; Jean Hoffman-Censits; Marijo Bilusic; Yu-Ning Wong; Alexander Kutikov; Rosalia Viterbo; Richard E Greenberg; David Y T Chen; Costas D Lallas; Edouard J Trabulsi; Roman Yelensky; David J McConkey; Vincent A Miller; Erica A Golemis; Eric A Ross
Journal:  Eur Urol       Date:  2015-08-01       Impact factor: 20.096

4.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration.

Authors:  Helga Thorvaldsdóttir; James T Robinson; Jill P Mesirov
Journal:  Brief Bioinform       Date:  2012-04-19       Impact factor: 11.622
  4 in total
  76 in total

Review 1.  DNA Damage and Repair Biomarkers of Immunotherapy Response.

Authors:  Kent W Mouw; Michael S Goldberg; Panagiotis A Konstantinopoulos; Alan D D'Andrea
Journal:  Cancer Discov       Date:  2017-06-19       Impact factor: 39.397

Review 2.  Molecular Characterization of Bladder Cancer.

Authors:  Thenappan Chandrasekar; Annette Erlich; Alexandre R Zlotta
Journal:  Curr Urol Rep       Date:  2018-11-03       Impact factor: 3.092

3.  Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Authors:  N Vasdev; H Zargar; J P Noël; R Veeratterapillay; A S Fairey; L S Mertens; C P Dinney; M C Mir; L M Krabbe; M S Cookson; N E Jacobsen; N M Gandhi; J Griffin; J S Montgomery; E Y Yu; E Xylinas; N J Campain; W Kassouf; M A Dall'Era; J A Seah; C E Ercole; S Horenblas; S S Sridhar; J S McGrath; J Aning; S F Shariat; J L Wright; T M Morgan; T J Bivalacqua; S North; D A Barocas; Y Lotan; P Grivas; A J Stephenson; J B Shah; B W van Rhijn; S Daneshmand; P E Spiess; J M Holzbeierlein; A Thorpe; P C Black
Journal:  World J Urol       Date:  2018-06-07       Impact factor: 4.226

Review 4.  [Predictive biomarkers in bladder cancer].

Authors:  H Reis; T Szarvas
Journal:  Pathologe       Date:  2019-12       Impact factor: 1.011

Review 5.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

Review 6.  Emerging biomarkers and targeted therapies in urothelial carcinoma.

Authors:  Prateek Mendiratta; Petros Grivas
Journal:  Ann Transl Med       Date:  2018-06

Review 7.  Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management.

Authors:  Aadel A Chaudhuri; Bruna Pellini; Nadja Pejovic; Pradeep S Chauhan; Peter K Harris; Jeffrey J Szymanski; Zachary L Smith; Vivek K Arora
Journal:  JCO Precis Oncol       Date:  2020-07-15

8.  Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.

Authors:  Ming Yin; Petros Grivas; Qi-En Wang; Amir Mortazavi; Hamid Emamekhoo; Sheldon L Holder; Joseph J Drabick; Michele Sue-Ann Woo; Sumanta Pal; Monali Vasekar; Edmund Folefac; Steven K Clinton; Paul Monk; Monika Joshi
Journal:  Oncologist       Date:  2020-05-13

9.  Enhanced power bacillus Calmette-Guérin-possibly too much of a good thing.

Authors:  Wojciech Krajewski; Sławomir Poletajew
Journal:  Transl Androl Urol       Date:  2019-12

10.  DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.

Authors:  Min Yuen Teo; Richard M Bambury; Emily C Zabor; Emmet Jordan; Hikmat Al-Ahmadie; Mariel E Boyd; Nancy Bouvier; Stephanie A Mullane; Eugene K Cha; Nitin Roper; Irina Ostrovnaya; David M Hyman; Bernard H Bochner; Maria E Arcila; David B Solit; Michael F Berger; Dean F Bajorin; Joaquim Bellmunt; Gopakumar Iyer; Jonathan E Rosenberg
Journal:  Clin Cancer Res       Date:  2017-01-30       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.